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risk or inoperable patients with symptomatic aortic valve stenosis, and research regarding
the use of transcatheter valves in intermediate or low-risk patients is currently ongoing. The
aim of this article is to provide comprehensive insight into the anesthetic management of pa-
tients undergoing TAVI and to highlight possible gaps in the current knowledge. One important
procedural characteristic that is imperative to consider is the type of anesthesia being used
and its possible complications. Increasingly, experienced centers have changed from general
anesthesia with endotracheal intubation to local anesthesia with sedation, especially when
the transfemoral access route is used for TAVI. There is still debate regarding what type of
anesthesia should be used in the procedure, and the lack of randomized data makes it even
more challenging for the operators.
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+ MODEL1. Introduction
Degenerative aortic valve stenosis (AS) is burdensome for
Western societies given the continuously increasing pop-
ulation that reaches 70, 80 or even 90 years of age. For
many decades, surgical aortic valve replacement (SAVR)
has been, and still is, the gold standard for effectively
treating patients with AS to ameliorate symptoms and
extend life. Nonetheless, approximately 30% of patients
are not offered SAVR due to increased surgical risk or
anatomical variations.1e4 Transcatheter aortic valve im-
plantation (TAVI) has emerged in the last decade as an
alternative to SAVR and has become the mainstay of
treatment for inoperable or high-surgical-risk patients
with severe AS.5,6 As the technology and operator expe-
rience advances, even patients with a moderate surgical
risk tend to undergo TAVI. Proper multidisciplinary pre-
and peri-procedural patient evaluation and management
is mandatory for achieving the best outcomes, especially
in patients who could otherwise be effectively treated
surgically. Cardiac anesthesiologists play an important
role in the decision making5 and peri-TAVI care of these
patients in the catheterization laboratory. The aim of this
review is to briefly discuss the TAVI procedure from an
anesthetist’s point of view, focusing on anesthetic man-
agement during TAVI, and to present the current data
regarding the use of general anesthesia (GA) versus local
anesthesia (LA) with conscious sedation, while high-
lighting the gaps in knowledge.2. Pre-procedural evaluation
A Heart Team comprised of cardiologists, interventional
cardiologists, heart surgeons and imaging specialists as-
sesses the suitability of all patients with aortic valve ste-
nosis for SAVR or TAVI. All patients are evaluated in a
detailed fashion and undergo several examinations,
including (but not limited to) an echocardiogram, coronary
angiogram and computed tomography scan. The decision to
perform TAVI is based on the severity of symptoms, evalu-
ation of risks and consideration of special (relative) con-
traindications to open heart surgery, such as previous heart
surgery, ‘hostile’ chest, and severe respiratory failure.
Surgical risk scores, such as the EuroSCORE (1 and 2)7,8 and
STS score9 are also considered, but they have many prob-
lems.10 Functional capability (for example, determined
with the Karnofsky index) can also provide valuable infor-
mation for decision-making.11 During the multidisciplinary
meeting where the access route and valve type are
considered, the input from the anesthesiologist regarding
the risk of the procedure and the type of anesthesia that
will be used is crucial.
The day before the procedure, the anesthesiologist has a
separate, detailed conversation with the patient, explain-
ing all anesthesia-related manipulations and possible com-
plications. Afterwards, the Anesthesia Informed Consent
form is signed. Pre-medication consists of omeprazole 40
mg and bromazepam, 1.5 mg per os the night before, and
the patient fasts for 8 h regardless of the anesthesia
technique that will be employed.Please cite this article in press as: Melidi E, et al., Cardio-anesthesiolo
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TAVI is performed in the cardiac catheterization laboratory
(i.e., cath lab) or in a hybrid operating room under strict
sterile conditions. Cardiac surgical backup in the hospital,
but not necessarily in the room, is mandatory.5,12 Although
the transfemoral route is considered to be the default and
best option for the procedure,13 other routes are available,
including the subclavian,14 trans-aortic15 and trans-apical
approaches.16 In a minority of patients, the arterial
vasculature is not accessible, and the trans-caval route is
another option in these cases.17,18
The availability of transcatheter valves has radically
increased in the past few years, and there is a vast selection of
available sizes that can be selected according to patient’s
anatomical characteristics as well as the operator and center
preference.19,20 The two most widely used valves are the
Edwards family (Edwards Lifesciences, Irvine, USA) and Med-
tronic family (Medtronic, Minnesota, USA) bioprosthetic valves.
The Edwards SAPIEN XT and SAPIEN 3 prostheses are balloon-
expandable and require aortic valve balloon predilatation and
rapid ventricular pacing (RVP) during deployment. The Med-
tronic CoreValve and Evolut R prostheses are self-expandable,
partially or wholly recapturable and repositionable.21 The
latter characteristic has reduced the incidence of implantation
of a second valve as a bail-out maneuver.22
TheMedtronic valves canalso be safely implantedwithout
balloon predilatation.23,24 Both valves can be implantedwith
the trans-femoral approach, but the Edwards valves can also
be implanted trans-apically, whereas the Medtronic valves
can be implanted by the subclavian and direct aortic routes.
Large randomized trials, including the PARTNER25e27 and
CoreValve US28e30 trials, have provided useful insight
regarding the mortality and complication rates after TAVI
with the two most widely used valves.
In recent years, even more TAVI devices have emerged,
including the Lotus valve (Boston Scientific Inc, USA),31 with
promising results for various procedural outcomes.
4. Anesthetic considerations
Our center (1st University Department of Cardiology, Hip-
pokration Hospital, Athens) was one of the very first TAVI
centers in Greece and has performed more than 400 im-
plantations since the beginning of 2009. At the start of the
TAVI program, all transfemoral procedures were performed
under GA. Subsequently, with gained experience and use of
newer devices, we have opted to perform more than 90% of
the implantations with only LA and mild sedation. When
surgical access is necessary, for example, with use of the
trans-subclavian route, GA is obviously mandatory.
All patients receive antibiotic prophylaxis (piperacillin-
tazobactam and/or vancomycin, dosage according to renal
function) 1 h before the procedure, and are on dual anti-
platelet treatment (100 mg acetylsalicylic acid and 75 mg
clopidogrel, daily).
4.1. General anesthesia (GA)
Invasive anesthesia monitoring consists of a three-lumen cen-
tral line (standard jugular veinaccess) for theadministrationofgy considerations for the trans-catheter aortic valve implantation
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line for invasive blood pressure monitoring and/or blood gas
control.A5e6Frenchsheath isalso inserted in the jugularvein,
which can be used by the cardiologist to fluoroscopically posi-
tiona temporarypacemakerwire in the rightventricleapex.All
lines are inserted once the patient lies on the cath lab table.
Basic non-invasive monitoring consists of pulse oximetry, cap-
nography, continuous multiple channel ECG and hourly urine
output through a bladder catheter.
Since the anesthetist controls the cardiac pacing, we
will briefly provide details. During balloon inflation in cases
of aortic valvuloplasty, a brief run of rapid ventricular
pacing at 170e200 beats per minute is necessary to drop
the blood pressure below 50 mmHg systolic and facilitate
immobility of the expanding balloon. The same maneuver is
performed during expansion of balloon-expandable pros-
theses, i.e., those of the Edwards family. After each run,
the pacemaker is reverted to 50 beats per minute back-up
pacing; in rare occasions (2e5%) where the valvuloplasty
results in a severe aortic regurgitation, fast pacing of
approximately 100e120 bpm is used to stabilize the patient
during the few minutes that are necessary to deploy the
prosthesis.
The choice of anesthetic agents varies. Induction is
usually performed with the use of midazolam, ketamine,
fentanyl and etomidate, or propofol, which are titrated
accordingly; all but the last are considered cardiovascular
stable drugs that do not cause a clinically significant drop in
the blood pressure and/or pulse rate. However, some pa-
tients may require inotropic and/or vasopressor support
before the induction of anesthesia; therefore, infusion
drips of noradrenaline (and less often adrenaline or phen-
ylephrine) are prepared and ready to be administered.
Rocuronium is used to facilitate endotracheal intubation.
Generally, however, the manner of drug administration
(dosage, etc.), rather than which specific drug is used, is
more important for achieving hemodynamic stability during
anesthesia induction and endotracheal intubation. Hemo-
dynamic collapse in an elderly, frail patient with significant
aortic valve stenosis provides very little time and few op-
tions before full-blown cardiac arrest.
The maintenance of anesthesia is achieved with a
target-controlled infusion of propofol. An added benefit of
GA and endotracheal intubation is the option to perform
trans-esophageal echocardiography (TEE) during the TAVI
procedure, either routinely or on an as-needed basis. The
latter is the protocol in our center.
4.2. Local anesthesia (LA) and sedation
All invasive lines are inserted in the same way as that
described for the GA approach. Oxygen is administered
with a partial rebreathing face-mask, and end-tidal carbon
dioxide is measured (capnography). LA is performed by the
interventional cardiologist per standard techniques (2%
lidocaine injection bilaterally in the two groin areas).
Sedation is performed by the anesthesiologist and consists
of target-controlled administration of midazolam, propo-
fol, fentanyl or remifentanil alone or in various dosage
combinations. The dosage and rate of administration are
individualized and titrated to the desired effect, according
to clinically relevant factors, including concomitantPlease cite this article in press as: Melidi E, et al., Cardio-anesthesiolo
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patient debilitation. In all cases, access to the patient is
such that the airway can be secured easily, if needed.
5. Choice of anesthesia
The most important anesthetic consideration in TAVI is the
type of anesthesia that will be given to the patient. Trends
vary within hospitals and countries, and numerous factors
need to be considered before reaching a decision, including
patient-related and operational factors as well as logis-
tics.32 In the early years of TAVI, GA was the default
option33e36; as previously mentioned, this was also the
standard in our hospital.
GA enables the use of either two- or three-dimensional
TEE, which can theoretically assist in optimal valve
deployment and prompt recognition of complications, such
as tamponade, interference with the mitral valve or para-
valvular leakage. Although the use of TEE with GA and
sedation has been described,37 most centers (including
ours) with adequate experience do not perform TEE;
instead, they rely on transthoracic echocardiogram (TTE),
angiography and hemodynamic measurements. Multi-slice
computed tomography is routinely utilized for valve size
selection, whereas the probe from the TEE interferes with
fluoroscopic imaging during valve deployment; however, a
pigtail catheter in the non-coronary cusp is sufficient for
guiding the procedure.38
Operators use GA in cases where the trans-femoral route
is not possible and surgery is involved, including the sub-
clavian,14 trans-aortic15 and trans-apical16 routes. Although
subclavian cases have been reported with LA, most centers
still prefer GA for these TAVI cases.39e41
Another theoretical argument in favor of GA is the total
immobility of the patient, which could decrease compli-
cations. However, available evidence does not support this
concern, indicating that the type of anesthesia is irrelevant
to the occurrence of vascular complications.34,35,41e44
The type of the anesthetic management has increasingly
switched from GA to LA, especially in European centers.45
Sedation shortens procedural time, time to ambulation
and hospital stay duration.34 In addition, the use of vaso-
pressors in sedation is not as frequent as in GA procedures,
which can be attributed to the vasodilating effects of the
anesthetic agents.46,47 Furthermore, emergency intubation
and switching to GA can be achieved in the cath lab to
surgically handle cardiac or vascular complications should
they arise during TAVI.48,49
LA has the unique benefit of real-time evaluation of the
patient’s mental status and cognitive function. Favorable
outcomes with a shorter implant procedure time, reduced
stay in high dependency areas, and shorter time to hospital
discharge have been reported in a series of patients who
underwent TAVI under sedation with remifentanil.34
6. Post-procedural care
After the procedure, patients are transferred to the coro-
nary care unit (CCU) for observation; GA patients are
extubated in the cath lab and are then transferred to the
CCU. For transfemoral TAVI, simple analgesics or low dosegy considerations for the trans-catheter aortic valve implantation
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gesia is only required when a surgical incision has been
made. After the procedure, improvements in systolic and
diastolic functions are often observed due to afterload
lowering, thus allowing for reduction or even discontinua-
tion of inotropic drugs.50 Sometimes high levels of crystal-
loids (i.e., normal saline, 0.9%) are needed during the
initial post-procedural hours to support a chronically hy-
pertrophied small left ventricle.
In uncomplicated cases of the “modern” TAVI era that
use 14 French devices, the patient is mobilized after 24 h.
In cases where there is no need for ECG monitoring, for
example, if a permanent pacemaker was in place prior to
the TAVI procedure, the patient is discharged after 2 to 3
days. In experienced centers, early discharge after the
procedure is becoming more prevalent; same-day discharge
has been described in a patient who underwent trans-
femoral TAVI with LA.51 However, it must be emphasized
that same-day discharge is not yet safe or common.7. Complications
From the available data, there is no difference between GA
and LA in terms of mortality.45,52 European data have shown
that patients with high EuroSCORE levels undergoing TAVI
with GA have a higher mortality, highlighting the need for
better evaluation and the possible use of LA in these
patients.38
It is also an important to monitor renal function after the
procedure. Impaired renal function before TAVI is considered
a prognostic factor for mortality after the procedure.53 Many
factors can influence renal function during the procedure,
including the amount and type of contrast, the incidence of
debris embolization during valvuloplasty and/or valve
deployment and the occurrence of hypotensive episodes
triggered by anesthetic agents.38 Recent reports have shown
higher rates ofacute kidney injury in theGApopulation,which
are attributed to episodes of hypotension.52,54,55 However,
there remains a lack of robust data regarding any possible
effect the type of anesthesia might have on kidney function.
Pacemaker implantation after TAVI is another important
consideration, and rates vary depending on the valve type
that is being used, the depth of implantation and the ex-
istence of previous conduction defects.56e59 While multiple
TAVI registries have not found any difference between the
anesthesia type and pacemaker implantation rates,32,45 one
single registry did.52 Nonetheless, it is inconclusive whether
the type of anesthesia impacts the incidence of pacemaker
implantation.
One of the most feared complications during TAVI is the
possibility of a stroke. It has been reported that patients are
more worried about stroke than death.50 Both PARTNER trial
cohorts, comparing the Edwards TAVI with either SAVR or
medical therapy, showed an increase in the rates of stroke in
the TAVI population during the first year.25,27 Longer follow-
up data from this trial have shown that at 5 years, the rates of
stroke in both the TAVI and SAVR populations are equal.60
Data from available trials and studies have not shown any
association between the types of anesthesia and the rates of
strokeafter TAVI.45,52,61 In theory, because LAhas thebenefit
of real-time evaluation of the patient’s mental status andPlease cite this article in press as: Melidi E, et al., Cardio-anesthesiolo
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treated, more easily and quickly.
From a financial point of view, frequent reports suggest
that LA with sedation in TAVI is more cost-effective
compared to GA since it requires less hospital staff and a
shorter length of hospital stay; however, reliable data are
still needed.54,62,63
8. Clinical implications
The rates of TAVI procedures have increased in the past
decade, enabling more patients with symptomatic aortic
stenosis to be successfully treated. Interestingly, this in-
crease in the use of TAVI has not decreased the number of
SAVR procedures performed, indicating the importance of
TAVI in meeting a previously unmet need for these pa-
tients.64 However, it is still unknown whether this might
change in the future, as the number of TAVI procedures
could eventually surpass SAVR procedures. The crucial
determining factor for this shift will be newer indications
for TAVI that we presume are forthcoming, including use in
intermediate- and lower-risk populations and in patients
with bicuspid aortic valves or failing bioprosthetic valves.65
The type of anesthesia during TAVI is an ongoing matter
for debate. There is a wealth of data that can be found in
various registries and studies, but no randomized controlled
trials. There has been a steady change in practice with the
ongoing trend to use local anesthesia with mild sedation
more; this approach has many potential benefits, including
shorter operative time, direct communication with the
patient, potentially lower complication rates and reduced
need for intra-procedural vasopressor support. However,
there remains a need for GA, especially when unconven-
tional access routes are indicated. The importance of the
presence of a dedicated and experienced cardiac-
anesthetist at the patient’s head at all times during the
TAVI procedure cannot be overemphasized. All described
anesthesia steps should be meticulously followed to assist
the interventional cardiologists in the procedure and to
minimize complications and immediately help resolve them
should they occur.
9. Conclusion
Transcatheter aortic valve implantation is a promising
treatment strategy for high-risk surgical patients, and trials
investigating its effectiveness in intermediate- and lower-
risk patients are underway. Data are inconsistent regarding
the superiority of using local anesthesia with conscious
sedation alone versus general anesthesia as the anesthesia
management of choice for elderly frail patients. Ultimately
and at present, the choice of anesthesia is based on the
personal experience and preference of the Heart Team
involved in the TAVI procedure, which will dictate the best
possible management plan for each patient.References
1. Iung B, Baron G, Butchart EG, et al. A prospective survey of
patients with valvular heart disease in Europe: The Euro Heartgy considerations for the trans-catheter aortic valve implantation
i.org/10.1016/j.hjc.2016.10.001
Cardio-anesthesiology in TAVI 5
+ MODELSurvey on Valvular Heart Disease. Eur Heart J. 2003;24:
1231e1243.
2. Varadarajan P, Kapoor N, Bansal RC, Pai RG. Clinical profile and
natural history of 453 nonsurgically managed patients with
severe aortic stenosis. Ann Thorac Surg. 2006;82:2111e2115.
3. Pai RG, Kapoor N, Bansal RC, Varadarajan P. Malignant natural
history of asymptomatic severe aortic stenosis: benefit of
aortic valve replacement. Ann Thorac Surg. 2006;82:
2116e2122.
4. Toutouzas K, Drakopoulou M, Synetos A, et al. In vivo aortic
valve thermal heterogeneity in patients with nonrheumatic
aortic valve stenosis the: first in vivo experience in humans. J
Am Coll Cardiol. 2008;52:758e763.
5. Vahanian A, Alfieri O, Andreotti F, et al, Joint Task Force on the
Management of Valvular Heart Disease of the European Society
of Cardiology, European Association for Cardio-Thoracic Sur-
gery. Guidelines on the management of valvular heart disease
(version 2012). Eur Heart J. 2012;33:2451e2496.
6. Latsios G, Gerckens U, Grube E. Trans-catheter percutaneous
aortic valve implantation for severe inoperable aortic valve
stenosis: where do we stand? Hellenic J Cardiol. 2010;51:
348e355.
7. Roques F, Michel P, Goldstone AR, Nashef SA. The logistic
EuroSCORE. Eur Heart J. 2003;24:881e882.
8. Nashef SA, Roques F, Sharples LD, et al. EuroSCORE II. Eur J
Cardiothorac Surg. 2012;41:734e744. discussion 744-5.
9. O’Brien SM, Shahian DM, Filardo G, et al, Society of Thoracic
Surgeons Quality Measurement Task F. The Society of Thoracic
Surgeons 2008 cardiac surgery risk models: part 2-isolated
valve surgery. Ann Thorac Surg. 2009;88:S23eS42.
10. Toutouzas K, Stefanadis C. Prediction models in transcatheter
aortic valve implantation: solid data or prophecies of Pythia?
Cardiology. 2013;126:12e14.
11. Buellesfeld L, Wenaweser P, Gerckens U, et al. Transcatheter
aortic valve implantation: predictors of procedural successethe
Siegburg-Bern experience. Eur Heart J. 2010;31:984e991.
12. Toutouzas K, Synetos A, Latsios G, et al. The requirement of
extracorporeal circulation system for transluminal aortic valve
replacement: do we really need it in the catheterization lab-
oratory? Catheter Cardiovasc Interv. 2015 May 6. http:
//dx.doi.org/10.1002/ccd.25988 [Epub ahead of print].
13. Webb JG, Altwegg L, Boone RH, et al. Transcatheter aortic
valve implantation: impact on clinical and valve-related out-
comes. Circulation. 2009;119:3009e3016.
14. Petronio AS, De Carlo M, Bedogni F, et al. Safety and efficacy of
the subclavian approach for transcatheter aortic valve im-
plantation with the CoreValve revalving system. Circ Car-
diovasc Interv. 2010;3:359e366.
15. Latsios G, Gerckens U, Grube E. Transaortic transcatheter
aortic valve implantation: a novel approach for the truly “no-
access option” patients. Catheter Cardiovasc Interv. 2010;75:
1129e1136.
16. Walther T, Arsalan M, Kim W, Kempfert J. TAVI: trans-
apicalewhat else? EuroIntervention. 2013;9(suppl l):S19e24.
17. Greenbaum AB, O’Neill WW, Paone G, et al. Caval-aortic ac-
cess to allow transcatheter aortic valve replacement in
otherwise ineligible patients: initial human experience. J Am
Coll Cardiol. 2014;63:2795e2804.
18. Lederman RJ, O’Neill WW, Greenbaum AB. Transcaval access
for TAVR across a polyester aortic graft. Catheter Cardiovasc
Interv. 2015;85:1270e1273.
19. Toutouzas KP, Stathogiannis KE, Latsios GS, Synetos AG,
Stefanadis CI. Recent valves used for transluminal implantation
in patients with aortic valve stenosis. Recent Pat Cardiovasc
Drug Discov. 2012;7:206e215.
20. Figulla HR, Webb JG, Lauten A, Feldman T. The transcatheter
valve technology pipeline for treatment of adult valvular heart
disease. Eur Heart J. 2016;37:2226e2239.Please cite this article in press as: Melidi E, et al., Cardio-anesthesiolo
(TAVI) procedure, Hellenic Journal of Cardiology (2016), http://dx.do21. Stathogiannis K, Synetos A, Toutouzas K, et al. Medtronic Cor-
eValve: achieving optimal outcomes. Hellenic J Cardiol. 2015;
56(suppl A):4e8.
22. Latsios G, Toutouzas K, Tousoulis D, et al. Case reports of bail-
out maneuvers for implantation of a second core valve pros-
thesis during the same TAVI procedure. Int J Cardiol. 2013;167:
e134ee136.
23. Grube E, Naber C, Abizaid A, et al. Feasibility of transcatheter
aortic valve implantation without balloon pre-dilation: a pilot
study. JACC Cardiovasc Interv. 2011;4:751e757.
24. Toutouzas K, Latsios G, Stathogiannis K, et al. One-year out-
comes after direct transcatheter aortic valve implantation
with a self-expanding bioprosthesis. A two-center international
experience. Int J Cardiol. 2016;202:631e635.
25. Smith CR, Leon MB, Mack MJ, et al, Investigators PT. Trans-
catheter versus surgical aortic-valve replacement in high-risk
patients. N Engl J Med. 2011;364:2187e2198.
26. Kodali SK, Williams MR, Smith CR, et al, Investigators PT. Two-
year outcomes after transcatheter or surgical aortic-valve
replacement. N Engl J Med. 2012;366:1686e1695.
27. Makkar RR, Fontana GP, Jilaihawi H, et al, Investigators PT.
Transcatheter aortic-valve replacement for inoperable severe
aortic stenosis. N Engl J Med. 2012;366:1696e1704.
28. Adams DH, Popma JJ, Reardon MJ, et al, Investigators USCC.
Transcatheter aortic-valve replacement with a self-expanding
prosthesis. N Engl J Med. 2014;370:1790e1798.
29. Reardon MJ, Adams DH, Kleiman NS, et al. 2-year outcomes in
patients undergoing surgical or self-expanding transcatheter
aortic valve replacement. J Am Coll Cardiol. 2015;66:113e121.
30. Deeb GM, Reardon MJ, Chetcuti S, et al, CoreValve USCI. 3-
Year outcomes in High-risk patients who underwent surgical
or transcatheter aortic valve replacement. J Am Coll Cardiol.
2016;67:2565e2574.
31. Meredith Am IT, Walters DL, Dumonteil N, et al. Transcatheter
aortic valve replacement for severe symptomatic aortic ste-
nosis using a repositionable valve system: 30-day primary
endpoint results from the REPRISE II study. J Am Coll Cardiol.
2014;64:1339e1348.
32. Brecker SJ, Bleiziffer S, Bosmans J, et al, Investigators AS.
Impact of anesthesia type on outcomes of transcatheter aortic
valve implantation (from the multicenter ADVANCE study). Am
J Cardiol. 2016;117:1332e1338.
33. Covello RD, Maj G, Landoni G, et al. Anesthetic management of
percutaneous aortic valve implantation: focus on challenges
encounteredandproposedsolutions. JCardiothoracVascAnesth.
2009;23:280e285.
34. Behan M, Haworth P, Hutchinson N, Trivedi U, Laborde JC,
Hildick-Smith D. Percutaneous aortic valve implants under
sedation: our initial experience. Catheter Cardiovasc Interv.
2008;72:1012e1015.
35. Billings 4th FT, Kodali SK, Shanewise JS. Transcatheter aortic
valve implantation: anesthetic considerations. Anesth Anal-
gesia. 2009;108:1453e1462.
36. Klein AA, Webb ST, Tsui S, Sudarshan C, Shapiro L, Densem C.
Transcatheter aortic valve insertion: anaesthetic implications
of emerging new technology. Br J Anaesth. 2009;103:792e799.
37. Guarracino F, Cabrini L, Baldassarri R, et al. Noninvasive
ventilation for awake percutaneous aortic valve implantation
in high-risk respiratory patients: a case series. J Cardiothorac
Vasc Anesth. 2011;25:1109e1112.
38. Dall’Ara G, Eltchaninoff H, Moat N, et al, Transcatheter Valve
Treatment Sentinel Registry Investigators of the EurObserva-
tional Research Programme of the European Society of Cardi-
ology. Local and general anaesthesia do not influence outcome
of transfemoral aortic valve implantation. Int J Cardiol. 2014;
177:448e454.
39. Petronio AS, De Carlo M, Bedogni F, et al. 2-year results of
CoreValve implantation through the subclavian access: agy considerations for the trans-catheter aortic valve implantation
i.org/10.1016/j.hjc.2016.10.001
6 E. Melidi et al.
+ MODELpropensity-matched comparison with the femoral access. J Am
Coll Cardiol. 2012;60:502e507.
40. Guarracino F, Covello RD, Landoni G, et al. Anesthetic manage-
mentof transcatheteraorticvalve implantationwithtransaxillary
approach. J Cardiothorac Vasc Anesth. 2011;25:437e443.
41. Ruggeri L, Gerli C, Franco A, et al. Anesthetic management for
percutaneous aortic valve implantation: an overview of
worldwide experiences. HSR Proc Intensive Care Cardiovasc
Anesth. 2012;4:40e46.
42. Covello RD, Landoni G, Michev I, et al. Percutaneous aortic
valve implantation: the anesthesiologist perspective. HSR Proc
Intensive Care Cardiovasc Anesth. 2009;1:28e38.
43. Grube E, Schuler G, Buellesfeld L, et al. Percutaneous aortic
valve replacement for severe aortic stenosis in high-risk pa-
tients using the second- and current third-generation self-
expanding CoreValve prosthesis: device success and 30-day
clinical outcome. J Am Coll Cardiol. 2007;50:69e76.
44. Basciani RM, Eberle B. Percutaneous aortic valve implants
under sedation: our initial experience. Catheter Cardiovasc
Interv. 2009;74:148e149. author reply 150.
45. Oguri A, Yamamoto M, Mouillet G, et al, Investigators FR.
Clinical outcomes and safety of transfemoral aortic valve im-
plantation under general versus local anesthesia: subanalysis
of the French Aortic National CoreValve and Edwards 2 regis-
try. Circ Cardiovasc Interv. 2014;7:602e610.
46. Balanika M, Smyrli A, Samanidis G, et al. Anesthetic manage-
ment of patients undergoing transcatheter aortic valve im-
plantation. J Cardiothorac Vasc Anesth. 2014;28:285e289.
47. Mayr NP, Michel J, Bleiziffer S, Tassani P, Martin K. Sedation or
general anesthesia for transcatheter aortic valve implantation
(TAVI). J Thorac Dis. 2015;7:1518e1526.
48. Bergmann L, Kahlert P, Eggebrecht H, Frey U, Peters J,
Kottenberg E. Transfemoral aortic valve implantation under
sedation and monitored anaesthetic careea feasibility study.
Anaesthesia. 2011;66:977e982.
49. Latsios G, Toutouzas K, Tousoulis D, et al. Prosthetic aortic
valve removal from the abdominal aorta after successful
“valve-through” TAVI. Int J Cardiol. 2013;164:e27ee28.
50. Franco A, Gerli C, Ruggeri L, Monaco F. Anaesthetic manage-
ment of transcatheter aortic valve implantation. Ann cardiac
Anaesth. 2012;15:54e63.
51. Genereux P, Demers P, Poulin F. Same day discharge after
transcatheter aortic valve replacement: are we there yet?
Catheter Cardiovasc Interv. 2016;87:980e982.
52. Petronio AS, Giannini C, De Carlo M, et al. Anaesthetic man-
agement of transcatheter aortic valve implantation: results
from the Italian CoreValve registry. EuroIntervention. 2016;12:
381e388.Please cite this article in press as: Melidi E, et al., Cardio-anesthesiolo
(TAVI) procedure, Hellenic Journal of Cardiology (2016), http://dx.do53. Ferro CJ, Chue CD, de Belder MA, et al, Group UTS, National
Institute for Cardiovascular Outcomes R. Impact of renal
function on survival after transcatheter aortic valve implan-
tation (TAVI): an analysis of the UK TAVI registry. Heart. 2015;
101:546e552.
54. Motloch LJ, Rottlaender D, Reda S, et al. Local versus general
anesthesia for transfemoral aortic valve implantation. Clin Res
Cardiol. 2012;101:45e53.
55. Barbanti M, Latib A, Sgroi C, et al. Acute kidney injury after
transcatheter aortic valve implantation with self-expanding
CoreValve prosthesis: results from a large multicentre Italian
research project. EuroIntervention. 2014;10:133e140.
56. Spargias K, Toutouzas K, Chrissoheris M, et al. The Athens TAVR
Registry of newer generation transfemoral aortic valves: 30-
day outcomes. Hellenic J Cardiol. 2013;54:18e24.
57. Gilard M, Eltchaninoff H, Iung B, et al, Investigators F. Registry
of transcatheter aortic-valve implantation in high-risk pa-
tients. N. Engl J Med. 2012;366:1705e1715.
58. Ussia GP, Barbanti M, Petronio AS, et al, CoreValve Italian
Registry I. Transcatheter aortic valve implantation: 3-year
outcomes of self-expanding CoreValve prosthesis. Eur Heart
J. 2012;33:969e976.
59. Toutouzas K, Michelongona A, Synetos A, Latsios G, Tsioufis C,
Stefanadis C. Atrioventricular block 9 days after transcatheter
aortic valve implantation. Int J Cardiol. 2011;151:112e114.
60. Mack MJ, Leon MB, Smith CR, et al, investigators Pt. 5-year
outcomes of transcatheter aortic valve replacement or surgi-
cal aortic valve replacement for high surgical risk patients with
aortic stenosis (PARTNER 1): a randomised controlled trial.
Lancet. 2015;385:2477e2484.
61. D’Errigo P, Ranucci M, Covello RD, et al, Group OR. Outcome
after general anesthesia versus monitored anesthesia care in
transfemoral transcatheter aortic valve replacement. J Car-
diothorac Vasc Anesth. 2016 Oct;30(5):1238e1243.
62. Durand E, Borz B, Godin M, et al. Transfemoral aortic valve
replacement with the Edwards SAPIEN and Edwards SAPIEN XT
prosthesis using exclusively local anesthesia and fluoroscopic
guidance: feasibility and 30-day outcomes. JACC Cardiovasc
Interv. 2012;5:461e467.
63. Babaliaros V, Devireddy C, Lerakis S, et al. Comparison of
transfemoral transcatheter aortic valve replacement per-
formed in the catheterization laboratory (minimalist approach)
versus hybrid operating room (standard approach): outcomes
and cost analysis. JACC Cardiovasc Interv. 2014;7:898e904.
64. Hamm CW, Arsalan M, Mack MJ. The future of transcatheter
aortic valve implantation. Eur Heart J. 2016;37:803e810.
65. Drakopoulou M, Toutouzas K, Tousoulis D. Are all valves for all
aortas? Hellenic J Cardiol. 2015;56:429e431.gy considerations for the trans-catheter aortic valve implantation
i.org/10.1016/j.hjc.2016.10.001
